Purpose: T790M is a mechanism underlying acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). We hypothesized that a synergistic com bination of cytotoxic drugs and EG FR-TKIs m ay overcome resistance. Materials and Methods: The antiproliferative effects and cell cycle distributions following treatm ents with Erlotinib (E) and cytotoxic drugs (C) were studied using a lung cancer cell line (NCI-H1975) harboring two m utations (L858R and T790M) in the EGFR gene. The cell viability assay and cell cycle analysis were conducted via an MTT assay and flow cytometry. The results of the treatm ents in different sequences were assessed using the com bination index. Results: Antagonism s were noted when erlotinib was administered before cytotoxic drugs (EC sequence), whereas synergisms were observed when pre-treatm ent with cytotoxic drugs was adm inistered before erlotinib (CE sequence). Treatm ent in the EC sequence arrested the cells in G 0/G 1 phase and reduced the apoptotic fraction. However, treatm ent in the CE sequence arrested the cells in the G2/M and S phase and a trend toward higher fractions of apoptotic cell death was observed. 
INTRODUCTION
Since the year 2000, lung cancer has been the leading cause of cancer death in South Korea, as in many other parts of the world. Many cytotoxic agents have been developed for lung cancer, but the platinum doublets with third-generation chemotherapeutic agents have achieved plateaus in efficacy. In the Eastern corporative oncology group's 1594 trial, in which chemotherapy regimens for advanced non-small cell lung cancer (NSCLC) were compared, no difference was detected in efficacy and survival between the four arms using different platinum doublet regimens (1) .
Recently, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were developed and employed for the treatment of refractory NSCLC. EGFR gene mutations (2) and amplifications (3) are known to be independent predictors of response to EGFR-TKIs.
The combination of EGFR-TKIs and cytotoxic drugs may prove to be a useful strategy against lung cancers with wild-type Treatment with EGFR-TKIs in cell lines expressing wild-type EGFR typically results in a G1 cell cycle arrest, whereas pronounced apoptosis is characteristic of cell lines with EGFR mutations (10) . Several previous studies have demonstrated that these cell cycle effects result in a negative interaction between concurrently administered chemotherapy and EGFR-TKIs in human lung cancer cell lines with mutant K-ras (11) and in a human esophageal squamous cancer cell line (12) .
Despite the dramatic responses to EGFR-TKI, the majority of responders ultimately relapse. A second mutation, T790M, is one mechanism of acquired resistance to EGFR-TKIs (13) .
In order to overcome the acquired resistance, second generation EGFR inhibitors have been developed and are being studied.
We hypothesized that a synergistic combination of cytotoxic drugs and EGFR-TKI may overcome resistance in cell lines harboring T790M.
MATERIALS AND METHODS

1) Reagents
Docetaxel, paclitaxel, and gemcitabine were provided by Sanofi Aventis Korea, BMS Pharmaceuticals Korea, and Lilly Korea. Erlotinib was provided by Hoffmann-La Roche.
2) Cell lines
The human lung cancer cell line NCI-H1975 derived from pulmonary adenocarcinoma was acquired from the American Type Culture Collection (Rockville, MD, USA). This cell line harbors two mutations (L858R and T790M) in the EGFR gene (13) . We selected this cell line to observe the combination effect of EGFR-TKI and cytotoxic drugs with an EGFR-TKI resistant cell line, as the T790M mutation of the EGFR gene is known to result in gefitinib resistance. Cells were maintained in RPMI 1640 (Gibco BRL, Grand Island, NY, USA), supplemented with 10% heat-inactivated fetal bovine serum, 20 mmol/L HEPES (pH 7.4), penicillin (100 IU/mL), streptomycin (100 μg/mL), and 4 mmol/L glutamine (Invitrogen Corp., Carlsbad, CA, USA) in a humidified atmosphere of 95% air and 5% CO2 at 37 o C.
3) Evaluation of antiproliferative effects
The antiproliferative activity of single agent treatment was E→T denotes pretreatment with Erlotinib followed by Paclitaxel, while T→E denotes Paclitaxel treatment followed by Erlotinib.
Comparisons of values were made between pairs of treatment sequences; E followed by cytotoxic drugs vs. cytotoxic drugs followed by E. E: erlotinib, T: paclitaxel, D: docetaxel, G: gemcitabine. *p＜0.05, † p＜0.01, ‡ p＜0.001. Flowcytometric analysis after treatment with erlotinib and cytotoxic drugs evidenced different patterns (Fig. 1) . In this resistant cell line harboring the T790M mutation, erlotinib treatment resulted in no detectable sub-G1 accumulation, an indicator of apoptosis. However, treatment with docetaxel and paclitaxel resulted in significant increases in the S and G2/M fractions. Gemcitabine resulted in a significant accumulation of sub-G1 fractions (Table 1) .
2) Antiproliferative effects according to combination sequences
Various combinations of cytotoxic drugs and erlotinib evidenced different antiproliferative effects on the NCI-H1975 cell line. The growth inhibitory effects of combination treatments are shown in Fig. 2 . Pretreatment with erlotinib evidenced the least profound cytotoxic effect, whereas treatment with cytotoxic drugs followed by erlotinib evidenced the most profound cytotoxic effects.
As is shown in Table 2 , antagonisms (CI＞1) were noted when erlotinib was administered before cytotoxic drugs (EC sequence), whereas synergisms (CI＜1) were noted when cytotoxic drugs were pre-treated before EGFR-TKIs (CE sequence).
3) Flowcytometric cell cycle analysis according to combination sequences
Flow cytometric analyses of cell cycle distributions revealed that treatment in the EC sequence arrested the cells in the G0/G1 phase and reduced the apoptotic fraction. However, treatments in the CE sequence arrested the cells in the G2/M phase and a trend toward higher fractions of apoptotic cell death were noted (Table 3) .
Despite an apparent lack of cytotoxicity from single-agent erlotinib, combined cytotoxic drug treatments in CE sequences resulted in additive sub-G1 accumulation as compared to what
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was observed in the EC sequences.
DISCUSSION AND CONCLUSION
The schedule-dependent cytotoxic effects of cytotoxic drugs and EGFR-TKIs have been addressed in previous studies.
However, these studies have used esophageal squamous carcinoma cell lines (12) In the current study, using a EGFR-TKI-resistant lung cancer cell line with the T790M mutation, we also demonstrated a negative interaction of erlotinib on the effect of cytotoxic drugs.
However, we could observe significant enhancement of the antitumor effect when we administered cytotoxic drugs followed by erlotinib. Erlotinib, while minimally active as a single agent in this resistant cell line, nevertheless potentiated the activity of docetaxel, paclitaxel, and gemcitabine in the schedule of cytotoxic drugs followed by erlotinib.
When erlotinib was administered before cytotoxic drugs, cell accumulation in G1 was observed, potentially limiting cytotoxic drug-induced damage during the S-through M-phases of the cell cycle. By way of contrast, when cytotoxic drugs were administered first, M or S-phase accumulation was observed.
The addition of erlotinib to cells that have a continued arrest period might increase the incidence of entry into apoptotic pathways. However, as we examined this interaction with a single cell line only, further validation will be needed with other cell lines.
Upon these theoretical bases, subsequent clinical studies combining cytotoxic drugs and EGFR-TKIs utilize an intermittent dosing schedule (18) . Pharmatokinetic separation was noted when docetaxel was administered after erlotinib and its metabolites were cleared (19) . In a recently published randomized phase 2 trial, Riely et al. (20) reported higher efficacy of pharmacodynamic separation using erlotinib and carboplatin/paclitaxel in patients with NSCLC.
In conclusion, our study demonstrated the schedule-dependent effect of cytotoxic drugs and erlotinib in the NSCLC cell line with T790M mutation, which is a second EGFR mutation detected in progressed NSCLC following treatment with EGFR-TKIs. The sequential treatment of cytotoxic chemotherapy followed by EGFR-TKI may overcome EGFR-TKI resistance.
